News

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...
Eli Lilly is tagging along on actress Kym Whitley’s blockbuster summer in a fresh Zepbound partnership with the “Happy ...
LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.
A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...
Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.
Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...
Kiran Musunuru, a University of Pennsylvania cardiologist and leading gene-editing researcher, thinks it’s possible. Musunuru cofounded Verve Therapeutics, a company developing a therapy that uses ...
Pharmaceutical giants introduce an insurance-free pathway for top anticoagulant Eliquis, following similar direct-to-patient ...
GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity ...
More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...
Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.